WEIGAO GROUP (01066): Shandong Weigao Orthopaedic Device (688161.SH) reported a net profit attributable to shareholders of approximately 132 million yuan in the first half of the year, a decrease of 6.85% compared to the same period last year.

WEIGAO GROUP (01066) announced the mid-term performance of Shandong Weigao Orthopaedic Device (688161.SH) for 2026, reporting operating revenue of approximately 704 million yuan, a year-on-year decrease of 4.93%; net profit attributable to shareholders of the listed company was approximately 132 million yuan, a year-on-year decrease of 6.85%; basic earnings per share were 0.33 yuan, with a cash dividend of 0.90 yuan per 10 shares (tax included). The announcement stated that the slight decline in revenue and net profit was primarily due to the seasonal fluctuations in clinical surgery volumes at domestic terminals, intensified market competition, and the progress of bulk procurement during the reporting period, which led to a slight decrease in the sales volume of the company's main products in the short term. However, the company's development momentum remains positive, particularly in the expansion of the sports medicine product line, post-investment integration of the minimally invasive orthopedic product line, overseas product registration and market expansion, and ongoing research and innovation.